AURA earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -3.96. Updated 2026-07-23.
Aura Biosciences (AURA) Research Hub
Aura Biosciences (AURA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.995 USD (-2.85%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.96, market cap 0.45B. This hub links to the full technical, earnings and options research available for AURA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.995 USD (-2.85%) |
| 52-week range | 6.25 USD – 8.37 USD |
| Trend regime | Range |
| 14-day RSI | 23.5 (Oversold) |
| Trailing P/E | -3.96 |
| Market cap | 0.45B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for AURA
Covered Call on AURA: how it works, illustrative setup around the real 7 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AURA: how it works, illustrative setup around the real 7 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AURA: how it works, illustrative setup around the real 7 USD price, max profit/loss, breakeven and when to use it. Educational.
AURA technical analysis: range, last 6.995 USD, RSI 23.5, 52w range 6.25 USD–8.37 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AURA in?
Aura Biosciences (AURA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AURA in an uptrend or downtrend?
As of 2026-09-11, AURA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AURA's trailing P/E ratio?
AURA's trailing P/E is -3.96, with a market cap of 0.45B. See the earnings research page for full valuation detail.
When does AURA next report earnings?
AURA is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.41 USD.